Methods for treating vascular malformations
The present disclosure relates to methods for inhibiting TIE2 kinase useful in the treatment of growth of venous malformations. Specifically, the disclosure relates to methods of using a compound of Formula I and salts thereof
1 . A method for reducing the average vascular area of TIE2 kinase-mediated vascular anomalies or TIE2 kinase mutant-mediated vascular anomalies, in a human patient in need thereof, consisting of administering to the patient a pharmaceutical composition comprising a compound of Formula I:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in an amount sufficient to administer the patient about 25 mg to about 300 mg, once or twice daily, of the compound, wherein the compound is administered to the patient as a single agent.
2 . The method of claim 1 , wherein the pharmaceutically acceptable salt is tosylate.
3 . The method of claim 1 , wherein the TIE2 kinase-mediated vascular anomalies or TIE2 kinase mutant-mediated vascular anomalies are slow-flow malformations.
4 . The method of claim 3 , wherein the slow-flow malformations are selected from capillary malformations, lymphatic malformations, or venous malformations.
5 . The method of claim 4 , wherein the slow-flow malformations are venous malformations.
6 . The method of claim 1 , wherein the patient is administered about 25 mg to about 150 mg of the compound of Formula I once or twice daily.
7 . The method of claim 1 , wherein the patient is administered about 100 mg of the compound of Formula I once or twice daily.
8 . The method of claim 1 , wherein the patient is administered about 150, 200, or 300 mg of the compound of Formula I once or twice daily.
9 . A method for reducing the average vascular area of venous malformations in a human patient in need thereof, consisting of administering to the patient a pharmaceutical composition comprising a compound of Formula I:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in an amount sufficient to administer the patient about 100 mg to about 200 mg, once or twice daily, of the compound, wherein the compound is administered to the patient as a single agent.
10 . The method of claim 1 , wherein the patient is administered about 25 mg of the compound of Formula I once daily.
11 . The method of claim 1 , wherein the patient is administered about 25mg of the compound of Formula I twice daily.
12 . The method of claim 1 , wherein the patient is administered about 50 mg of the compound of Formula I once daily.
13 . The method of claim 1 , wherein the patient is administered about 50 mg of the compound of Formula I twice daily.